Search results for "tofacitinib"

showing 2 items of 12 documents

SAT0132 DOES JANUS KINASE INHIBITION INDUCED HYPERLIPIDAEMIA ASSOCIATE WITH AN INCREASE OF AORTIC STIFFNESS IN PATIENTS WITH ARTHRITIS? PRELIMINARY R…

2020

Background:Treatment with Janus Kinase inhibitors (JAK-i) (Tofacitinib, Baricitinib) can cause an increase of serum lipids such as total cholesterol, low- (LDL) and high- (HDL) density lipoproteins in patients with arthritis (1). On the other hand, JAK-i can reduce systemic inflammation and have therefore a beneficial effect on the cardiovascular system of treated patients. However, the effects of JAK-i on the CV system have not been adequately examined. In particular, we are not aware of any ’’real world’’ data concerning CV risk of patients receiving JAK-i treatment.Stiffness of the aortic vasculature is a modifiable, valid and independent surrogate predictor of CV risk and can be measure…

medicine.medical_specialtyTofacitinibmedicine.diagnostic_testbusiness.industryImmunologyArthritisBlood lipidsmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyPsoriatic arthritisRheumatologyInternal medicineRheumatoid arthritisArterial stiffnessCardiologyImmunology and AllergyMedicinebusinessLipid profilePulse wave velocityAnnals of the Rheumatic Diseases
researchProduct

Tofacitinib in active ulcerative colitis

2012

ulcerative colitis.tofacitinibSettore MED/09 - Medicina Interna
researchProduct